Efficacy and safety of peginterferon alfa-2a (40KD) in HBeAg-positive chronic hepatitis B patients

Journal of Gastrointestinal and Liver Diseases

Volumn 18, Issue 4, 2009, Pages 425-431

  Cǎruntu, Florin Alexandru ^a   Streinu Cercel, Adrian ^a   Gheorghe, Liliana Simona ^b   Grigorescu, Mircea ^c   Sporea, Ioan ^d   Stanciu, Carol ^e   Andronescu, Dan ^f   Voinea, Florea ^g   Diculescu, Mircea ^b   Oproiu, Alexandru ^h   Voiosu, Radu ⁱ  

^a Matei Bals Infectious Diseases Institute   (Romania)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c EMERGENCY COUNTY HOSPITAL   (Romania)

^d Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

^e Institute of Gastroenterology and Hepatology   (Romania)

^f Universitary Emergency Hospital   (Romania)

^g Emergency County Hospital   (Romania)

^h Agrippa Ionescu Emergency Hospital   (Romania)

ⁱ V Babes National Institute of Pathology   (Romania)

Author keywords

Alanine aminotransferase; Chronic hepatitis B; Hepatitis B e antigen; Hepatitis B virus; Interferon a 2a; Viral DNA

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBODY PRODUCTION; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OTITIS MEDIA; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RECTUM HEMORRHAGE; RECURRENT DISEASE; RELAPSE; SCREENING; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; TRACHEOBRONCHITIS; TREATMENT RESPONSE; URTICARIA; VIRUS INHIBITION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; ROMANIA; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 74949095498     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25 Suppl 1: 3-8.
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49 (5 Suppl): S45-S55.
3. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
4. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 49 (5 Suppl): S96-S102.
5. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803.
6. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
8. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49 (5Suppl): S4-S12.
9. Wong SN, Lok AS. Treatment of hepatitis B: who, when, and how? Arch Intern Med 2006; 166: 9-12.
10. Yang H, Westland CE, Delaney WE IV, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473.
11. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
12. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-891.
13. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
14. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427.
15. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
16. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
17. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-1319.
18. Yuen MF, Yuan HJ, Wong DK, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005; 54: 1610-1614.
19. Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment in chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001; 34: 1021-1026.